Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol

作者
Chenyan Zhang,Heqi Yang,Chang Chen,Ruizhen Li,Junjie Xiong,Deying Kang,Du He,Xi-Jiao Liu,Ke Cheng,Dan Cao
出处
期刊:BMJ Open [BMJ]
卷期号:14 (7): e084274-e084274 被引量:2
标识
DOI:10.1136/bmjopen-2024-084274
摘要

INTRODUCTION: Patients with pancreatic ductal adenocarcinoma (PDAC) remain a poor prognosis despite the development of chemotherapy. Although programmed cell death 1 (PD-1) blockade has shown great efficacy in various solid tumours, its application in treating PDAC is limited. Recent studies have indicated that chemotherapy or stereotactic body radiotherapy (SBRT) may improve the antitumour effect of PD-1 blockade in patients with PDAC. The objective of this study is to evaluate the efficacy and safety of combined therapy comprising PD-1 blockade, gemcitabine plus nab-paclitaxel chemotherapy and SBRT for patients with metastatic PDAC. METHODS AND ANALYSIS: nab-paclitaxel on days 1 and 8 of the 21-day cycle. Serplulimab (200 mg) will be administered intravenously on day 1 of the 21-day cycle. Furthermore, during the second cycle, the patients will undergo SBRT with doses of 33 Gy in five fractions for primary lesions or doses of 24 Gy in three fractions for metastases. The primary endpoint is the 6-month progression-free survival (PFS) rate. The secondary endpoints overall survival, PFS, overall response rate, disease control rate, time to progression, duration of response, duration of disease control and safety. Moreover, this trial seeks to investigate biomarkers such as circulating tumour DNA and circulating hybrid cells in patients diagnosed with metastatic PDAC. ETHICS AND DISSEMINATION: The study was approved by the Ethics Committee on Biomedical Research, West China Hospital of Sichuan University. The study results will be presented at international conferences and published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ChiCTR2300073237.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hbhsjk发布了新的文献求助10
刚刚
水煮电吹风的应助被刘之捷采纳,获得10
刚刚
刚刚
1秒前
小二郎的应助被youyyuy采纳,获得10
1秒前
zhouzhou完成签到,获得积分10
1秒前
上课呢完成签到 ,获得积分10
1秒前
psycancan完成签到 ,获得积分10
1秒前
2秒前
现代的向珊完成签到,获得积分20
2秒前
2秒前
2秒前
2秒前
456完成签到 ,获得积分10
3秒前
3秒前
Yiii完成签到,获得积分10
3秒前
3秒前
Ken发布了新的文献求助10
3秒前
4秒前
大胆鞯完成签到,获得积分10
4秒前
木木完成签到,获得积分10
5秒前
科研通AI6.3的应助被小胖采纳,获得10
5秒前
zmaifyc完成签到,获得积分10
5秒前
5秒前
Running完成签到 ,获得积分10
6秒前
傅敬业发布了新的文献求助10
6秒前
阿楠发布了新的文献求助10
6秒前
yanjia发布了新的文献求助150
6秒前
6秒前
sly完成签到,获得积分20
6秒前
6秒前
6秒前
322小弟发布了新的文献求助10
6秒前
7秒前
时尚的咖啡完成签到,获得积分10
7秒前
7秒前
魔法翼龙完成签到,获得积分10
7秒前
刘翰焜发布了新的文献求助10
7秒前
周周发布了新的文献求助10
8秒前
周周发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287